Email updates

Keep up to date with the latest news and content from BMC Molecular Biology and BioMed Central.

Open Access Research article

Serum repressing efflux pump CDR1 in Candida albicans

Yun-Liang Yang1, Yi-Hsuan Lin2, Ming-Yang Tsao2, Chia-Geun Chen2, Hsin-I Shih1, Jen-Chung Fan2, Jang-Shiun Wang23 and Hsiu-Jung Lo2*

Author Affiliations

1 Department of Biological Science and Technology, National Chiao Tung University, Hsinchu

2 Division of Clinical Research, National Health Research Institutes, Miaoli

3 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China

For all author emails, please log on.

BMC Molecular Biology 2006, 7:22  doi:10.1186/1471-2199-7-22

Published: 13 July 2006

Abstract

Background

In the past decades, the prevalence of candidemia has increased significantly and drug resistance has also become a pressing problem. Overexpression of CDR1, an efflux pump, has been proposed as a major mechanism contributing to the drug resistance in Candida albicans. It has been demonstrated that biological fluids such as human serum can have profound effects on antifungal pharmacodynamics. The aim of this study is to understand the effects of serum in drug susceptibility via monitoring the activity of CDR1 promoter of C. albicans.

Results

The wild-type C. albicans cells (SC5314) but not the cdr1/cdr1 mutant cells became more susceptible to the antifungal drug when the medium contained serum. To understand the regulation of CDR1 in the presence of serum, we have constructed CDR1 promoter-Renilla luciferase (CDR1p-RLUC) reporter to monitor the activity of the CDR1 promoter in C. albicans. As expected, the expression of CDR1p-RLUC was induced by miconazole. Surprisingly, it was repressed by serum. Consistently, the level of CDR1 mRNA was also reduced in the presence of serum but not N-acetyl-D-glucosamine, a known inducer for germ tube formation.

Conclusion

Our finding that the expression of CDR1 is repressed by serum raises the question as to how does CDR1 contribute to the drug resistance in C. albicans causing candidemia. This also suggests that it is important to re-assess the prediction of in vivo therapeutic outcome of candidemia based on the results of standard in vitro antifungal susceptibility testing, conducted in the absence of serum.